BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
See today's BioWorld
Home
» Rigel Chasing Pfizer in RA; Nabs $1.2B-Plus AstraZeneca Alliance
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Rigel Chasing Pfizer in RA; Nabs $1.2B-Plus AstraZeneca Alliance
Feb. 17, 2010
By
Jennifer Boggs
No Comments
Armed with some big pharma muscle in the form of a potential $1 billion-plus deal with AstraZeneca plc, Rigel Pharmaceuticals Inc. is hot on Pfizer Inc.'s heels in the race for an oral, disease-modifying rheumatoid arthritis drug. (BioWorld Today)
BioWorld